The US Department of Agriculture approved the genetically modified purple tomato to extend its shelf life and boost nutritional quality almost 15 years after its development.
According to biochemist Cathie Martin, she and her colleagues at Norfolk Plant Scientists (NPS) have been experimenting with pigment production in flowering plants for over two decades, and they've spent almost 15 months developing the purple tomato.
The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
Domesticated tomatoes already have genes to produce anthocyanins, but they are not 'turned on.' By carefully adding two genes, the tomatoes and juice become a rich source of antioxidants, because purple pigments are made in the whole tomato, not just the skins.
While there are already some purple-skinned tomatoes, their pigments mostly stop at the outer layers and don't accumulate in the fruit itself.
The NPS also emphasized that there is increasing evidence to show that antioxidants work much better when consumed within foods.
The USDA Animal and Plant Health Inspection Service (APHIS) reported that the tomato was modified to alter its color and enhance its nutritional quality, adding that the plant is unlikely to pose an increased plant pest risk compared to other cultivated tomatoes.
Nathan Pumplin, the CEO of NPS' US-based commercial business, said they are optimistic that they can begin limited distribution of purple tomatoes in the US by 2023.


Goldman Sachs Raises Oil Price Forecasts Amid Strait of Hormuz Disruptions
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
U.S. Futures Slide as Iran Denies Nuclear Talks with Washington
Oil Prices Rebound as Iran Denies U.S. Talks, Middle East Tensions Persist
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



